US$ 27.05
glp 1 muscle mass loss Study finds GLP-1 receptor agonists target fat over for weight GLP-1/GIP loses superior potency over
Description
Heart failure is a common complication of obesity [61, 62], and clinical trials have shown that GLP-1 analogs, particularly tirzepatide, can improve cardiac function and reduce the risk of heart failure in people with obesity [63]
Ty Gluckman from the Providence Center for Cardiovascular Analytics, Research + Data Science (CARDS) and researchers from Truveta, is helping to fill these gaps

Torti M, Vacca L, Stocchi F

Patoulias D, Michailidis T

doi: 10.1210/me.2014-1273
